Clinical Benefit of High-Sensitivity KRAS Mutation Testing in Metastatic Colorectal Cancer Treated with Anti-EGFR Antibody Therapy

Oncology, 04/30/2012

The findings suggest that high–sensitivity KRAS mutation testing is useful for selecting true responders to cetuximab.

Print Article Summary